US
China
Canada
Japan
Germany
UK
France
Brazil
Italy
Ecuador
Saudi Arabia
Spain
India
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
Regeneron PharmaceuticalsClinical trials
19 active trials in UK, Germany, France, Italy, Spain and Russia
Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease NCT07181109
- A Study to Evaluate ALN-4915 in Adult Healthy Volunteers NCT07535606
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism NCT07430397
Top trial sponsors (worldwide)
- Alnylam Pharmaceuticals 10 active trials on ClinicalTrials.gov (opens in a new tab)
- Regeneron Pharmaceuticals 7 active trials on ClinicalTrials.gov (opens in a new tab)
- Novartis AG 5 active trials on ClinicalTrials.gov (opens in a new tab)
- Ribocure Pharmaceuticals AB 3 active trials on ClinicalTrials.gov (opens in a new tab)
- ADARx Pharmaceuticals, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
See every trial on ClinicalTrials.gov (opens in a new tab)